King Luther Capital Management Corp Trims Stake in Medpace Holdings, Inc. $MEDP

King Luther Capital Management Corp cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,592 shares of the company’s stock after selling 3,269 shares during the period. King Luther Capital Management Corp’s holdings in Medpace were worth $9,045,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of MEDP. Fifth Third Wealth Advisors LLC increased its stake in shares of Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after purchasing an additional 19 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the period. Portside Wealth Group LLC increased its position in Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after buying an additional 27 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Medpace by 35.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares in the last quarter. Finally, M&T Bank Corp grew its stake in shares of Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MEDP. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a research note on Tuesday, February 10th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $483.45.

Insider Activity at Medpace

In related news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 201,745 shares of company stock worth $122,369,738 over the last ninety days. Insiders own 20.30% of the company’s stock.

Medpace Stock Up 0.1%

Shares of MEDP stock opened at $446.44 on Friday. The company’s fifty day simple moving average is $558.09 and its two-hundred day simple moving average is $537.81. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The stock has a market cap of $12.67 billion, a P/E ratio of 29.18, a PEG ratio of 2.14 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue was up 32.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.